Pharmacology of N-benzyladriamycin-14-valerate in the rat

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 5, 1999, Pages 419-426

  Sweatman, Trevor W ^a   Seshadri, Ramakrishnan ^a   Israel, Mervyn ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Animal pharmacology; Anthracycline; Chemotherapy; Metabolism

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; N BENZYLDOXORUBICIN 14 VALERATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CELL POPULATION; CONTROLLED STUDY; DOSE KIDNEY FUNCTION RELATION; DRUG ACCUMULATION; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; INTRAVENOUS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; INJECTIONS, INTRAVENOUS; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032988799     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050917     Document Type: Article

References (24)

1. Bertazzoli C, Bellini O, Magrini U, Tosana MG (1979) Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat Rep 63: 1877-1883
2. Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, Giuliani FC, Silber R, Kirschenbaum S, Potmesil M (1989) DNA topoisomerase II interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res 49: 5969-5978
3. Danks MK, Yalowich JC, Beck WT (1987) Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide. Cancer Res 47: 1297-1301
4. Ganapathi R, Grabowski D, Sweatman TW, Seshadri R, Israel M (1989) N-Benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterization of cross-resistance in vitro and in vivo. Br J Cancer 60: 819-826
5. Israel M, Seshadri R (1986) N-Alkyl and N-benzyladriamycin derivatives. U.S. Patent 4 610 977, US Patent Office, Washington, DC
6. Israel M, Sweatman TW, Seshadri R, Koseki Y (1986) Metabolic studies in rats with N-benzyladriamycin-14-valerate (AD 198), a promising new anthracycline analog. Proc Am Assoc Cancer Res 27: 239
7. Israel M, Seshadri R, Koseki Y, Sweatman TW, Idriss JM (1987) Amelioration of adriamycin toxicity through modification of drug-DNA binding properties. Cancer Treat Rev 14: 163-167
8. Israel M, Sweatman TW, Seshadri R, Koseki Y (1989) Comparative uptake and retention of adriamycin and N-benzyladriamycin-14-valerate in human leukemic lymphocyte cell cultures. Cancer Chemother Pharmacol 25: 177-183
9. Israel M, Koseki Y, Jenkins JJ III (1991) Murine cardiotoxicity assay of the mechanistically novel adriamycin analog, N-benzyladriamycin-14-valerate (AD 198). Proc Am Assoc Cancer Res 32: 423
10. Krishan A, Sauerteig A, Gordon K, Swinkin C (1986) Flow cytometric monitoring of cellular anthracycline accumulation in murine leukemia cells. Cancer Res 46: 1768-1773
11. Lameh J, Chuang LF, Israel M, Chuang RY (1988) Mechanistic studies on N-benzyladriainycin-14-valerate (AD 198), a highly lipophilic alkyl adriamycin analogue. Anticancer Res 8: 689-694
12. Lothstein L, Sweatman TW, Dockter M, Israel M (1992) Resistance of N benzyladriamycin-14-valerate in mouse J774.2 cells: P-glycoprotein expression without reduced N-benzyladriamycin-14-valerate accumulation. Cancer Res 52: 3409-3417
13. Maniar N, Krishan A, Israel M, Samy TSA (1988) Anthracycline-indticed DNA breaks and resealing in doxorubicin-resistant murine leukemia P388 cells. Biochem Pharmacol 37: 1763-1772
14. Parke DV, Smith RL (eds) (1977) Drug metabolism from microbe to man. Taylor and Francis, London
15. Riggs CE (1992) Antitumor antibiotics and related compounds. In: Perry MC (ed) The chemotherapy source book, Williams and Wilkins, Baltimore, pp 318-358
16. Roaten JB, Bertics PJ, Wiepz G, Lothstein L, Israel M, Sweatman TW (1998) Protein kinase C inhibition by N-benzyladriamycin-14-valerate (AD 198). Proc Am Assoc Cancer Res 39: 306
17. Sweatman TW, Israel M (1987) Comparative metabolism and elimination of adriamycin and 4′ epi-adriamycin in the rat. Cancer Chemother Pharmacol 19:201-206
18. Sweatman TW, Israel M, Seshadri R, Koseki Y, Beck WT (1990) Cytotoxicity and cellular pharmacology of N-benzyladriamycin-14-valerate in mechanistically different multidrug-resistant human leukemic cells. J Cell Pharmacol 1: 96-102
19. Sweatman TW, Parker RF, Israel M (1991) Pharmacologic rationale for intravesical N trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study. Cancer Chemother Pharmacol 28: 1-6
20. Sweatman TW, Seshadri R, Israel M (1992) Selective retention of N-benzyladriamycin-14-valerate (AD 198) in the lung following intravenous drug administration. Proc Am Assoc Cancer Res 33: 520
21. Tavolini N, Guarino AM (1982) Does adriamycin undergo an enterohepatic circulation. Proc Soc Exp Biol Med 169: 41-46
22. Traganos F, Israel M, Seshadri R, Kirschenbaum S, Potmesil M (1985) Effects of new N-alkyl analogues of adriamycin on in vitro survival and cell-cycle progression. Cancer Res 45: 6273-6279
23. Williams RT (1959) Detoxication mechanisms. Wiley, New York
24. Yamaoka K, Nakagawa T, Uno T (1978) Application of Akaike Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet. Biopharm 6: 165-75